VESTAL POINT CAPITAL LP
Q1 2026 Form 13-F
NEW YORK, DELAWARE
CIK 0001974915
· CRD 325894
· SEC-registered investment adviser
$3.6B Reported Value Total
VESTAL POINT CAPITAL, LP reports 4 total accounts under management (AUM). There are 4 discretionary accounts valued at $5,469,117,378, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
1 fund
· $2.8B gross asset value
Hedge Fund: $2.8B
Source: Form ADV filed 2026-03-31
Reported value
$3.6B
Quarter over quarter
+4.5%
Holdings
90
Top-10 concentration
40.4%
Key People
Form ADV owners & control persons
Ryan Christopher Wilder
MANAGING PARTNER AND CHIEF INVESTMENT OFFICER
Ilko Latchezarov Menkov
PARTNER, COO AND CCO
Benjamin German Carroll
CHIEF FINANCIAL OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2026 13F record
Q1 2026 13F filing summary
| Period of report | March 31, 2026 |
|---|---|
| Filed | May 15, 2026 |
| Form | 13F-HR |
| Reported value | $3.6B |
| Positions | 90 |
| Change in reported value | +21.6% |
| New positions | 37 |
| Exited positions | 22 |
| Position turnover | 52.7% |
| Top-10 concentration | 40.4% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
68 | $4.3B |
|
Q1 2026 13F
Filed May 15, 2026
|
90 | $3.6B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
75 | $2.9B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
80 | $2.2B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
72 | $1.9B |
|
Q1 2025 13F
Filed May 15, 2025
|
63 | $1.4B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
73 | $1.7B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
67 | $1.3B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
60 | $1.3B |
|
Q1 2024 13F
Filed May 14, 2024
|
58 | $1.2B |
|
Q4 2023 13F
Filed Feb 13, 2024
|
48 | $944.0M |
Top 20 holdings · Q1 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | RVMD Revolution Medicines Inc | $231.0M | 6.46% |
| 2 | BMRN BioMarin Pharmaceutical Inc | $202.0M | 5.65% |
| 3 | ABVX Abivax SA | $167.0M | 4.67% |
| 4 | NBIX Neurocrine Biosciences Inc | $164.7M | 4.6% |
| 5 | ARWR Arrowhead Pharmaceuticals Inc | $142.6M | 3.99% |
| 6 | ELVN Enliven Therapeutics Inc | $127.4M | 3.56% |
| 7 | RGEN Repligen Corp | $109.0M | 3.05% |
| 8 | BCAX Bicara Therapeutics Inc | $107.9M | 3.02% |
| 9 | NRIX Nurix Therapeutics Inc | $100.8M | 2.82% |
| 10 | APGE Apogee Therapeutics Inc | $92.6M | 2.59% |
| 11 | ASND Ascendis Pharma A/S | $85.8M | 2.4% |
| 12 | IMCR Immunocore Holdings PLC | $83.4M | 2.33% |
| 13 | TSHA Taysha Gene Therapies Inc | $80.5M | 2.25% |
| 14 | DYN Dyne Therapeutics Inc | $72.5M | 2.03% |
| 15 | SNY Sanofi SA | $67.5M | 1.89% |
| 16 | BCRX BioCryst Pharmaceuticals Inc | $66.9M | 1.87% |
| 17 | SRRK Scholar Rock Holding Corp | $65.1M | 1.82% |
| 18 | IMTX Immatics NV | $60.8M | 1.7% |
| 19 | BMY Bristol-Myers Squibb Co | $60.7M | 1.7% |
| 20 | ALC Alcon AG | $60.3M | 1.69% |
Values as reported on the Q1 2026 Form 13F. Every position is in the holdings table below.